Modern Management of Advanced Pancreatic Cancer: Expert Guidance on Clinical Challenges

Gain expert guidance on the latest treatment of newly diagnosed and relapsed/refractory advanced pancreatic cancer in this 1-hour interactive meeting. Afterward, an associated downloadable slideset and 2 FAQ modules will be available on the CCO Web site to enhance the information presented at the live meetings.

Sign up now! Registration is complimentary.


Program Topics:

  • Diagnosis and staging considerations
  • Current therapeutic options for metastatic pancreatic cancer
  • Second-line agents for pancreatic cancer
  • Emerging agents for pancreatic cancer
  • Other signaling pathway targets in pancreatic cancer


Date / Time
Event Details


Program Director
Tanios Bekaii-Saab, MD, FACP

Mayo Clinic College of Medicine and Science
Co-Leader, GI Cancer Program
Mayo Clinic Cancer Center
Senior Associate Consultant
Mayo Clinic Arizona
Phoenix, Arizona

Program Director
Andrew Ko, MD

Division of Hematology/Oncology
Department of Medicine
University of California, San Francisco
San Francisco, California

Thomas Cartwright, MD

Associate Professor of Medicine
University of Central Florida School of Medicine
US Oncology GI Research Committee
Ocala, Florida

Elena Gabriela Chiorean, MD

Associate Professor of Medicine
Division of Hematology-Oncology
Department of Medicine
University of Washington
Seattle, Washington

Steven J. Cohen, MD

Associate Professor
Department of Hematology/Oncology
Chief, Gastrointestinal Medical Oncology
American Oncologic Hospital d/b/a The Hospital of Fox Chase Cancer Center
Medical Director
Fox Chase Cancer Center Partners
Philadelphia, Pennsylvania

Bassel F. El-Rayes, MD

Professor and Vice Chair for Clinical Research 
Department of Hematology and Medical Oncology
Associate Director for Clinical Research
Director, Gastrointestinal Oncology Program
Winship Cancer Institute of Emory University
Emory University School of Medicine
Atlanta, Georgia

Milind Javle, MD

Division of Cancer Medicine
Department of Gastrointestinal Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas

Daniel Laheru, MD

Professor of Oncology
Ian T. MacMillan Professorship in Clinical Pancreatic Cancer Research
Co-Director, Gastrointestinal Cancer Program
Co-Director, Skip Viragh Center for Pancreatic Cancer Research and Clinical Care
Member, Miller-Coulson Academy of Clinical Excellence
The Sidney Kimmel Comprehensive Cancer Center
The Johns Hopkins University School of Medicine
Baltimore, Maryland

Andrea Wang-Gillam, MD, PhD

Associate Professor of Medicine
Medical Oncology Section
Oncology Division
Department of Medicine
Washington University School of Medicine
St Louis, Missouri

Colin Weekes, MD, PhD

Associate Professor of Medicine
Director, Pancreas Medical Oncology Program
Division of Medical Oncology
University of Colorado, Denver
Aurora, Colorado


Goal Statement
The goal of this activity is to improve participants’ competence in treating patients with pancreatic cancer.

Target Audience
This program is intended for physicians, registered nurses, pharmacists, and other healthcare providers who care for patients with pancreatic cancer.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Apply current guidelines and clinical findings to select individualized therapies for patients with newly diagnosed advanced pancreatic cancer
  • Plan treatment strategies for patients with advanced pancreatic cancer after progression on first-line systemic therapy based on available data and treatment guidelines
  • Manage disease-related and treatment-related symptoms for patients with advanced pancreatic cancer


Physician Continuing Medical Education

Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Clinical Care Options, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Credit Designation
This educational activity for 1.0 contact hour is provided by Postgraduate Institute for Medicine.

Accreditation Statement
Postgraduate Institute for Medicine is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

Provider approved by the California Board of Registered Nursing, Provider Number 13485, for 1.0 contact hour.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you within 3 weeks.

Pharmacist Continuing Education
ACPE logo

Accreditation Statement
Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Credit Designation
Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - 0809-9999-17-454-L01-P

Type of Activity

Upon receipt of the completed activity evaluation form, you will receive an email from the Postgraduate Institute for Medicine within 3 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.